White label ELPA - ClinicalTrials.eu

Study of Encorafenib, Cetuximab, and Pembrolizumab for Patients with Untreated BRAF V600E-Mutant Metastatic Colorectal Cancer

Not recruiting

2 1 1 1
Investigated drugs:
+6
Study on BI 706321 and Ustekinumab for Patients with Moderate to Severe Crohn’s Disease

Not recruiting

2 1 1
Investigated diseases:
- Crohn’s disease
Investigated drugs:
- Bi 706321
- Ustekinumab
Study on the Safety and Effectiveness of Motixafortide and G-CSF for Stem Cell Collection in Patients with Multiple Myeloma

Not recruiting

3 1
Investigated diseases:
- Plasma cell myeloma
Investigated drugs:
- Motixafortide
Study on the Safety and Effectiveness of Ivosidenib or Enasidenib with Azacitidine for Patients with Newly Diagnosed Acute Myeloid Leukemia with IDH1 or IDH2 Mutations

Not recruiting

1 1 1 1
Investigated diseases:
- Acute myeloid leukaemia
Investigated drugs:
Study on MaaT013 for Treating Acute Gastrointestinal Graft-Versus-Host Disease in Patients Not Responding to Ruxolitinib

Not recruiting

3 1 1
Investigated diseases:
- Acute graft versus host disease in intestine
Investigated drugs:
- Allogeneic Faecal Microbiota, Pooled
Study on the Safety and Effectiveness of TAK-755 (Apadamtase Alfa) for Patients with Severe Congenital Thrombotic Thrombocytopenic Purpura (cTTP)

Not recruiting

3 1 1
Investigated diseases:
- Thrombotic thrombocytopenic purpura
Investigated drugs:
- Apadamtase Alfa
Study of Tucatinib and Ado-Trastuzumab Emtansine for Patients with Advanced HER2+ Breast Cancer

Not recruiting

3 1 1
Investigated diseases:
- Breast cancer
- Breast cancer metastatic
Investigated drugs:
- Trastuzumab Emtansine
- Tucatinib
+2
Study on JAB-21822 for Adults with Advanced Solid Tumors with KRAS G12C Mutation

Not recruiting

2 1 1
Investigated diseases:
- Neoplasm malignant
Investigated drugs:
- Jab-21822
Study of RVU120 for Patients with Advanced Solid Tumors After Standard Treatments Have Failed

Not recruiting

2 1 1 1
Investigated diseases:
- Neoplasm
Investigated drugs:
- 7,8-Dibromo-5,6-Dihydro-9-Methyl-2-(1-Piperazinyl)-4H-Imidazo[4,5,1-Ij]Quinoline Hydrochloride
Study on the Effects and Safety of Prasinezumab for Patients with Early Parkinson’s Disease

Not recruiting

4 1
Investigated diseases:
- Parkinson’s disease
Investigated drugs:
- Prasinezumab

Full Name *

e-Mail *

Country Prefix *

Phone Number *

Nationality *

Gender *

Check all consents

Check all consents

I accept the Terms and Conditions and Privacy Policy *

*I accept the Terms and Conditions and Privacy Policy

I consent to receiving commercial information from the Service Operator *

*I consent to receiving commercial information from the Service Operator

I consent to the use of telecommunications terminal equipment and automated calling systems by the Service Operator for marketing communication purposes *

*I consent to the use of telecommunications terminal equipment and automated calling systems by the Service Operator for marketing communication purposes

We use cookies